PD
PTGX icon

Point72 (DIFC)’s Protagonist Therapeutics PTGX Stock Holding History

Point72 (DIFC)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,415
Closed -$153K – 1747
2024
Q2 		$153K Buy
+4,415
New +$129K 0.01% 906

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 (DIFC)'s PTGX Position: Q3 2024 in Review

Point72 (DIFC) sold out of Protagonist Therapeutics (PTGX) in Q3 2024, closing a stake of 4,415 shares — an estimated $153K sold.

Point72 (DIFC) first reported a position in PTGX in Q2 2024 and held it in 1 quarter. The position peaked at $153K in Q2 2024. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Point72 (DIFC) reported no remaining Protagonist Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Point72 (DIFC) sold 4,415 Protagonist Therapeutics shares in Q3 2024, an estimated $153K.
  • Point72 (DIFC) first reported a position in Protagonist Therapeutics in Q2 2024 and held it in 1 quarter.
  • Point72 (DIFC)'s Protagonist Therapeutics position peaked at $153K in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Point72 (DIFC)'s 13F filing for Q3 2024, filed 14 Nov 2024.